DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
PAVINETANT
2
Small molecule
Investigational
Unknown
Unknown
Flushing; Polycystic Ovary Syndrome; Schizophrenia
Neurokinin 3 receptor antagonist
PAVINETANT
×
Maximum Phase:
2
First Approval:
None
UNII:
3U471ZVC5K
Molecule Type:
Small molecule
Molecular Formula:
C26H25N3O3S
Molecular Weight:
459.57
AlogP:
5.15
PSA:
88.16
HBD:
2.0
HBA:
#RotB:
7.0
Source:
CNV2197944
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies; Neuralgia, Postherpetic
Voltage-gated N-type calcium channel alpha-1B subunit blocker
CNV2197944
×
Maximum Phase:
2
First Approval:
None
UNII:
SSB9S6N20R
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALOVUDINE
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Unknown
ALOVUDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
PG53R0DWDQ
Molecule Type:
Small molecule
Molecular Formula:
C10H13FN2O4
Molecular Weight:
244.22
AlogP:
-0.54
PSA:
84.32
HBD:
2.0
HBA:
#RotB:
2.0
Source:
2-HYDROXYOLEIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Glioma; Glioblastoma
Unknown
2-HYDROXYOLEIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
OSV3KVO1BT
Molecule Type:
Small molecule
Molecular Formula:
C18H34O3
Molecular Weight:
298.47
AlogP:
5.08
PSA:
57.53
HBD:
2.0
HBA:
#RotB:
15.0
Source:
MERICITABINE
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
MERICITABINE
×
Maximum Phase:
2
First Approval:
None
UNII:
TA63JX8X52
Molecule Type:
Small molecule
Molecular Formula:
C18H26FN3O6
Molecular Weight:
399.42
AlogP:
1.22
PSA:
122.74
HBD:
1.0
HBA:
#RotB:
6.0
Source:
BMS-754807
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms
Insulin-like growth factor I receptor inhibitor
BMS-754807
×
Maximum Phase:
2
First Approval:
None
UNII:
W9E3353E8J
Molecule Type:
Small molecule
Molecular Formula:
C23H24FN9O
Molecular Weight:
461.51
AlogP:
3.61
PSA:
116.13
HBD:
3.0
HBA:
#RotB:
6.0
Source:
CIMLANOD
2
Small molecule
Investigational
Unknown
Unknown
Heart Failure
Unknown
CIMLANOD
×
Maximum Phase:
2
First Approval:
None
UNII:
2US4FK1EPV
Molecule Type:
Small molecule
Molecular Formula:
C5H7NO4S
Molecular Weight:
177.18
AlogP:
0.26
PSA:
79.54
HBD:
2.0
HBA:
#RotB:
2.0
Source:
LB-100
2
Small molecule
Investigational
Unknown
Unknown
Myelodysplastic Syndromes; Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Oligodendroglioma
Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform inhibitor
LB-100
×
Maximum Phase:
2
First Approval:
None
UNII:
0C1JUU9S0L
Molecule Type:
Small molecule
Molecular Formula:
C13H20N2O4
Molecular Weight:
268.31
AlogP:
-0.36
PSA:
70.08
HBD:
1.0
HBA:
#RotB:
2.0
Source:
SODIUM TUNGSTATE
2
Small molecule
Investigational
Unknown
Unknown
Obesity
Unknown
SODIUM TUNGSTATE
×
Maximum Phase:
2
First Approval:
None
UNII:
64LRH4405G
Molecule Type:
Small molecule
Molecular Formula:
Na2O4W
Molecular Weight:
293.82
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
INDIRUBIN
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis
Unknown
INDIRUBIN
×
Maximum Phase:
2
First Approval:
None
UNII:
V86L8P74GI
Molecule Type:
Small molecule
Molecular Formula:
C16H10N2O2
Molecular Weight:
262.27
AlogP:
2.66
PSA:
58.2
HBD:
2.0
HBA:
#RotB:
0.0
Source:
TERBOGREL
2
Small molecule
Investigational
Unknown
Unknown
Hypertension, Pulmonary
Thromboxane A2 receptor antagonist
TERBOGREL
×
Maximum Phase:
2
First Approval:
None
UNII:
5Z4KWQ5OGN
Molecule Type:
Small molecule
Molecular Formula:
C23H27N5O2
Molecular Weight:
405.5
AlogP:
4.41
PSA:
110.4
HBD:
3.0
HBA:
#RotB:
7.0
Source:
METHYLSAMIDORPHAN
2
Small molecule
Investigational
Unknown
Unknown
Constipation
Mu opioid receptor antagonist
METHYLSAMIDORPHAN
×
Maximum Phase:
2
First Approval:
None
UNII:
8347HC35J6
Molecule Type:
Small molecule
Molecular Formula:
C22H29N2O4+
Molecular Weight:
385.48
AlogP:
1.4
PSA:
100.62
HBD:
3.0
HBA:
#RotB:
3.0
Source:
OLODANRIGAN
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies; Neuralgia, Postherpetic
Angiotensin II type 2 (AT-2) receptor antagonist
OLODANRIGAN
×
Maximum Phase:
2
First Approval:
None
UNII:
P0FN522VTO
Molecule Type:
Small molecule
Molecular Formula:
C32H29NO5
Molecular Weight:
507.59
AlogP:
5.44
PSA:
76.07
HBD:
1.0
HBA:
#RotB:
8.0
Source:
SRX246
2
Small molecule
Investigational
Unknown
Unknown
Anxiety; Huntington Disease; Mood Disorders; Stress Disorders, Post-Traumatic
Vasopressin V1a receptor antagonist
SRX246
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C43H48F3N5O5
Molecular Weight:
771.88
AlogP:
6.6
PSA:
102.5
HBD:
1.0
HBA:
#RotB:
11.0
Source:
VAPITADINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
VAPITADINE
×
Maximum Phase:
2
First Approval:
None
UNII:
Z5014VUX83
Molecule Type:
Small molecule
Molecular Formula:
C17H20N4O
Molecular Weight:
296.37
AlogP:
1.21
PSA:
72.94
HBD:
2.0
HBA:
#RotB:
1.0
Source:
GW493838
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia
Adenosine A1 receptor agonist
GW493838
×
Maximum Phase:
2
First Approval:
None
UNII:
93OG0JL22O
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TETRAHYDROCANNABIVARIN
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
TETRAHYDROCANNABIVARIN
×
Maximum Phase:
2
First Approval:
None
UNII:
I5YE3I47D8
Molecule Type:
Small molecule
Molecular Formula:
C19H26O2
Molecular Weight:
286.42
AlogP:
4.96
PSA:
29.46
HBD:
1.0
HBA:
#RotB:
2.0
Source:
MB07811
2
Small molecule
Investigational
Unknown
Unknown
Hypercholesterolemia; Hyperlipidemias; Non-alcoholic Fatty Liver Disease
Thyroid hormone receptor beta-1 agonist
MB07811
×
Maximum Phase:
2
First Approval:
None
UNII:
3Z11398FNQ
Molecule Type:
Small molecule
Molecular Formula:
C28H32ClO5P
Molecular Weight:
514.99
AlogP:
8.08
PSA:
64.99
HBD:
1.0
HBA:
#RotB:
7.0
Source:
CANNABIDIOL ACID
2
Small molecule
Investigational
Unknown
Unknown
Hallux Valgus
Unknown
CANNABIDIOL ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
FJX8O3OJCD
Molecule Type:
Small molecule
Molecular Formula:
C22H30O4
Molecular Weight:
358.48
AlogP:
5.54
PSA:
77.76
HBD:
3.0
HBA:
#RotB:
7.0
Source:
DAROTROPIUM BROMIDE
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Muscarinic acetylcholine receptor antagonist
DAROTROPIUM BROMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
2W2V1U785A
Molecule Type:
Small molecule
Molecular Formula:
C24H29BrN2
Molecular Weight:
425.41
AlogP:
4.9
PSA:
23.79
HBD:
0.0
HBA:
#RotB:
4.0
Source:
EPALRESTAT
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Aldose reductase inhibitor
EPALRESTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
424DV0807X
Molecule Type:
Small molecule
Molecular Formula:
C15H13NO3S2
Molecular Weight:
319.41
AlogP:
2.92
PSA:
57.61
HBD:
1.0
HBA:
#RotB:
4.0
Source:
GUSPERIMUS
2
Small molecule
Investigational
Unknown
Unknown
Granulomatosis with Polyangiitis; Immune System Diseases
Unknown
GUSPERIMUS
×
Maximum Phase:
2
First Approval:
None
UNII:
UJ0ZJ76DO9
Molecule Type:
Small molecule
Molecular Formula:
C17H37N7O3
Molecular Weight:
387.53
AlogP:
-1.31
PSA:
178.38
HBD:
8.0
HBA:
#RotB:
17.0
Source:
TESMILIFENE
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Unknown
TESMILIFENE
×
Maximum Phase:
2
First Approval:
None
UNII:
I43T3ID6G2
Molecule Type:
Small molecule
Molecular Formula:
C19H25NO
Molecular Weight:
283.41
AlogP:
4.0
PSA:
12.47
HBD:
0.0
HBA:
#RotB:
8.0
Source:
ENOXOLONE
2
Small molecule
Investigational
Unknown
Unknown
Skin Ulcer
Unknown
ENOXOLONE
×
Maximum Phase:
2
First Approval:
None
UNII:
P540XA09DR
Molecule Type:
Small molecule
Molecular Formula:
C30H46O4
Molecular Weight:
470.69
AlogP:
6.41
PSA:
74.6
HBD:
2.0
HBA:
#RotB:
1.0
Source:
COSITECAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
COSITECAN
×
Maximum Phase:
2
First Approval:
None
UNII:
24R60NVC41
Molecule Type:
Small molecule
Molecular Formula:
C25H28N2O4Si
Molecular Weight:
448.6
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
DINALBUPHINE SEBACATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DINALBUPHINE SEBACATE
×
Maximum Phase:
2
First Approval:
None
UNII:
464OXX39Y6
Molecule Type:
Small molecule
Molecular Formula:
C52H68N2O10
Molecular Weight:
881.12
AlogP:
5.95
PSA:
158.46
HBD:
4.0
HBA:
#RotB:
15.0
Source:
ND0801
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity
Neuronal acetylcholine receptor protein alpha-7 subunit agonist
ND0801
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GLESATINIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung
Hepatocyte growth factor receptor inhibitor
GLESATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
7Q29OXD98N
Molecule Type:
Small molecule
Molecular Formula:
C31H27F2N5O3S2
Molecular Weight:
619.72
AlogP:
6.22
PSA:
97.4
HBD:
3.0
HBA:
#RotB:
11.0
Source:
4-ISOTHIOUREIDOBUTYRONITRILE
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Ovarian Neoplasms
Unknown
4-ISOTHIOUREIDOBUTYRONITRILE
×
Maximum Phase:
2
First Approval:
None
UNII:
C3059TG1KN
Molecule Type:
Small molecule
Molecular Formula:
C5H9N3S
Molecular Weight:
143.22
AlogP:
0.92
PSA:
73.66
HBD:
2.0
HBA:
#RotB:
3.0
Source:
EC-17
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Renal Cell
Unknown
EC-17
×
Maximum Phase:
2
First Approval:
None
UNII:
V7YQ6134AE
Molecule Type:
Small molecule
Molecular Formula:
C42H36N10O10S
Molecular Weight:
872.88
AlogP:
3.03
PSA:
310.33
HBD:
9.0
HBA:
#RotB:
13.0
Source:
MILVETEROL
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Beta-2 adrenergic receptor agonist
MILVETEROL
×
Maximum Phase:
2
First Approval:
None
UNII:
LGY1VQ9622
Molecule Type:
Small molecule
Molecular Formula:
C25H29N3O4
Molecular Weight:
435.52
AlogP:
2.97
PSA:
113.85
HBD:
6.0
HBA:
#RotB:
12.0
Source:
SERLOPITANT
2
Small molecule
Investigational
Unknown
Unknown
Epidermolysis Bullosa; Pruritus
Neurokinin 1 receptor antagonist
SERLOPITANT
×
Maximum Phase:
2
First Approval:
None
UNII:
277V92K32B
Molecule Type:
Small molecule
Molecular Formula:
C29H28F7NO2
Molecular Weight:
555.53
AlogP:
7.68
PSA:
29.54
HBD:
0.0
HBA:
#RotB:
5.0
Source:
EMICERFONT
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome; Phobia, Social
Corticotropin releasing factor receptor 1 antagonist
EMICERFONT
×
Maximum Phase:
2
First Approval:
None
UNII:
OJ8EG4264P
Molecule Type:
Small molecule
Molecular Formula:
C22H24N6O2
Molecular Weight:
404.47
AlogP:
3.12
PSA:
75.52
HBD:
1.0
HBA:
#RotB:
4.0
Source:
MIRIDESAP
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections; Amyloidosis
Serum amyloid P-component cross-linking agent
MIRIDESAP
×
Maximum Phase:
2
First Approval:
None
UNII:
WO97N24A47
Molecule Type:
Small molecule
Molecular Formula:
C16H24N2O6
Molecular Weight:
340.38
AlogP:
0.7
PSA:
115.22
HBD:
2.0
HBA:
#RotB:
7.0
Source:
SODIUM NITRATE
2
Small molecule
Investigational
Unknown
Unknown
Cardiomyopathy, Hypertrophic; Ischemia; Angina, Stable; Asthma; Coronary Disease; Muscular Dystrophy, Duchenne
Unknown
SODIUM NITRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
8M4L3H2ZVZ
Molecule Type:
Small molecule
Molecular Formula:
NNaO3
Molecular Weight:
84.99
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
1
2
…
96
97
98
99
100
101
102
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA